Berkeley Heights, NJ - May 19, 2005 -
Genta Incorporated (Nasdaq: GNTA) will present at the Needham &
Co. Biotechnology Conference in New York, NY. Raymond P.
Warrell, Jr., M.D., Genta's Chairman and Chief Executive Officer,
will discuss the Company's development programs on Thursday, May
26, 2005 at 1:30 pm EST.
A live audio webcast of the presentation can be accessed through
Genta's Investor Relations site at:
http://www.genta.com/genta/InvestorRelation/events.html
. A replay will be available approximately 24 hours following
the presentation and will be available for 30 days thereafter.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense® (oblimersen sodium) Injection, the
Company's lead compound from its oligonucleotide program is
currently undergoing late-stage, Phase 3 clinical testing.
The leading drug in Genta's small molecule program is Ganite®
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more
information about Genta, please visit our website at:
http://www.genta.com/
.
Genta Forward Looking Statement
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and
developments to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual Report/Form 10-K
for 2004.
SOURCE: Genta Incorporated
